Corona Remedies

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,920.80
73.1 (3.96%)
BSENSE

Jun 23, 12:01 PM

BSE+NSE Vol: 55.79 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

55.79 k (-51.24%) Volume

Shareholding (Mar 2026)

FII

2.25%

Held by 21 FIIs

DII

7.02%

Held by 9 DIIs

Promoter

69.00%

Why is Corona Remedies Ltd falling/rising?

23-Jun-2026

As of 22-Jun, the stock price of Corona Remedies Ltd is 1,847.70, down 0.85% after four days of gains, indicating a trend reversal. Despite recent declines, the stock has performed well over the past month and year, but reduced investor participation may signal a lack of confidence contributing to the current price drop.

As of 22-Jun, the stock price of Corona Remedies Ltd is currently at 1,847.70, reflecting a decrease of 15.8 points or 0.85%. This decline comes after a period of four consecutive days of gains, indicating a trend reversal. Additionally, the stock has underperformed its sector by 1.83% today, which may contribute to the downward movement in price.<BR><BR>Despite the current decline, the stock has shown strong performance over the past week and month, with increases of 6.96% and 9.83%, respectively. Year-to-date, it has risen by an impressive 33.33%, contrasting sharply with the Sensex, which has fallen by 9.54% during the same period. However, today's trading activity indicates a decrease in investor participation, as the delivery volume on June 19 fell by 46.17% compared to the five-day average. This reduced participation may signal a lack of confidence among investors, contributing to the stock's current decline.<BR><BR>On a positive note, the company remains fundamentally strong, being net-debt free and experiencing healthy long-term growth. Institutional investors have also increased their stake in the company by 0.66% over the previous quarter, which may provide some support for the stock in the long run. Nonetheless, the combination of recent price trends, underperformance against the sector, and declining investor participation are key factors contributing to the current fall in the stock price of Corona Remedies Ltd.

View full answer

Should I buy, sell or hold Corona Remedies Ltd?

19-Jun-2026

What does Corona Remedies do?

11-Jun-2026

Corona Remedies Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 353 Cr and a net profit of 45 Cr for March 2026, with a market cap of INR 10,856 Cr. Key metrics include a P/E ratio of 53.00 and a return on equity of 26.75%.

Overview:<BR>Corona Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The specific incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 353 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 45 Cr (Quarterly Results - Mar 2026) <BR>Market-cap: INR 10,856 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 53.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.16 <BR>Return on Equity: 26.75% <BR>Price to Book: 14.50 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

View full answer

How big is Corona Remedies?

11-Jun-2026

As of 10th June, Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, with recent net sales of 1,403.18 Cr and a net profit of 185.12 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,403.18 Cr, while the sum of Net Profit for the same period is 185.12 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 606.34 Cr, and Total Assets amount to 929.86 Cr.

View full answer

Who are the peers of the Corona Remedies?

11-Jun-2026

Corona Remedies' peers include Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, and Blue Jet Health. Most peers show Below Average growth and management risk, with Shilpa Medicare having the highest 1-year return at 15.43%, while Blue Jet Health has the lowest at -47.29%.

Peers: The peers of Corona Remedies are Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer and P & G Health Ltd, while Good management risk is found at Alivus Life, Marksans Pharma, and Blue Jet Health, and Average management risk is noted for Viyash Scientifi and Akums Drugs. Below Average management risk is present at Shilpa Medicare and Strides Pharma. All peers exhibit Below Average growth, except for Akums Drugs, which has Good growth. Capital Structure ratings show Excellent at Alivus Life, Marksans Pharma, Sanofi Consumer, P & G Health Ltd, and Blue Jet Health, while Good is observed at Akums Drugs, and Below Average at Shilpa Medicare, Viyash Scientifi, and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shilpa Medicare at 15.43%, while Blue Jet Health has the lowest at -47.29%. Corona Remedies' 1-year return is not available for comparison. Additionally, Blue Jet Health is the only peer with a negative six-month return.

View full answer

Has Corona Remedies Ltd declared dividend?

13-May-2026

Yes, Corona Remedies Ltd has declared a 100% dividend with an ex-date of June 19, 2026. However, the dividend yield is 0%, and total returns have been mixed, with a 7.52% return in the last 3 months but no returns over longer periods.

Corona Remedies Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 19 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%.<BR><BR>Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Corona Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that there has been no effective return from dividends in recent years. The total returns over various periods show a mixed performance, with a notable return in the last 3 months but no returns in the longer periods.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

  • Healthy long term growth as Operating profit has grown by an annual rate 0%
  • The company is Net-Debt Free
2

Flat results in Mar 26

3

With ROCE of 29.5, it has a Very Expensive valuation with a 13.2 Enterprise value to Capital Employed

4

Increasing Participation by Institutional Investors

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 11,666 Cr (Small Cap)

stock-summary
P/E

57.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.54%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

26.75%

stock-summary
Price to Book

15.15

Revenue and Profits:
Net Sales:
353 Cr
(Quarterly Results - Mar 2026)
Net Profit:
45 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.54%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.22%
0.64%
21.86%
6 Months
40.96%
0.74%
41.7%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 10.017765387558763 per share ex-dividend date: Jun-19-2026

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Corona Remedies Ltd Gains 7.82%: 5 Key Factors Driving the Week’s Momentum

Announcements stock-summary

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

19-Jun-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sepia Investments Ltd & Others

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011

19-Jun-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011

19-Jun-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Corona Remedies Ltd has declared 100% dividend, ex-date: 19 Jun 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
27.90
Debt to EBITDA (avg)
0.56
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.54
Tax Ratio
23.03%
Dividend Payout Ratio
30.00%
Pledged Shares
0
Institutional Holding
9.26%
ROCE (avg)
29.49%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
57
Industry P/E
34
Price to Book Value
15.15
EV to EBIT
44.70
EV to EBITDA
38.93
EV to Capital Employed
13.18
EV to Sales
8.14
PEG Ratio
NA
Dividend Yield
0.54%
ROCE (Latest)
29.49%
ROE (Latest)
26.75%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
No Signal
Bollinger Bands
Mildly Bullish
KST
Dow Theory
No Trend
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 17 Schemes (6.35%)

FIIs

Held by 21 FIIs (2.25%)

Promoter with highest holding

Ankurbhai K Mehta (22.0%)

Highest Public shareholder

Sepia Investments Limited (19.76%)

Individual Investors Holdings

0.77%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "353.09",
          "val2": "342.42",
          "chgp": "3.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "62.02",
          "val2": "83.16",
          "chgp": "-25.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.38",
          "val2": "1.66",
          "chgp": "-16.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-19.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "45.05",
          "val2": "41.25",
          "chgp": "9.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.56%",
          "val2": "24.29%",
          "chgp": "-6.73%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "707.67",
          "val2": "605.04",
          "chgp": "16.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "148.25",
          "val2": "116.34",
          "chgp": "27.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.92",
          "val2": "6.02",
          "chgp": "-34.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "98.55",
          "val2": "72.93",
          "chgp": "35.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.95%",
          "val2": "19.23%",
          "chgp": "1.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,050.09",
          "val2": "902.73",
          "chgp": "16.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "231.41",
          "val2": "185.76",
          "chgp": "24.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.58",
          "val2": "8.41",
          "chgp": "-33.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "139.80",
          "val2": "117.70",
          "chgp": "18.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.04%",
          "val2": "20.58%",
          "chgp": "1.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,403.18",
          "val2": "1,196.42",
          "chgp": "17.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "293.44",
          "val2": "239.98",
          "chgp": "22.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.97",
          "val2": "10.60",
          "chgp": "-34.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "184.85",
          "val2": "149.05",
          "chgp": "24.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.91%",
          "val2": "20.06%",
          "chgp": "0.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
353.09
342.42
3.12%
Operating Profit (PBDIT) excl Other Income
62.02
83.16
-25.42%
Interest
1.38
1.66
-16.87%
Exceptional Items
0.00
-19.10
100.00%
Standalone Net Profit
45.05
41.25
9.21%
Operating Profit Margin (Excl OI)
17.56%
24.29%
-6.73%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
707.67
605.04
16.96%
Operating Profit (PBDIT) excl Other Income
148.25
116.34
27.43%
Interest
3.92
6.02
-34.88%
Exceptional Items
0.00
0.00
Standalone Net Profit
98.55
72.93
35.13%
Operating Profit Margin (Excl OI)
20.95%
19.23%
1.72%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,050.09
902.73
16.32%
Operating Profit (PBDIT) excl Other Income
231.41
185.76
24.57%
Interest
5.58
8.41
-33.65%
Exceptional Items
-19.10
0.00
Standalone Net Profit
139.80
117.70
18.78%
Operating Profit Margin (Excl OI)
22.04%
20.58%
1.46%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,403.18
1,196.42
17.28%
Operating Profit (PBDIT) excl Other Income
293.44
239.98
22.28%
Interest
6.97
10.60
-34.25%
Exceptional Items
-19.10
0.00
Standalone Net Profit
184.85
149.05
24.02%
Operating Profit Margin (Excl OI)
20.91%
20.06%
0.85%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Corona Remedies Ltd stock-summary
stock-summary
Corona Remedies Ltd
Small Cap
Pharmaceuticals & Biotechnology
Corona Remedies Limited was originally incorporated as `CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, Company converted into a public limited and Company name has changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.
Company Coordinates stock-summary
Icon
No Company Details Available